EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB:FCSC.OB), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, today announced the first scientific presentation of data demonstrating the efficacy of LAVIV™ (azficel-T) in treating moderate-to-severe depressed acne scars. The data were presented at the American Society for Dermatologic Surgery (ASDS) annual meeting in Washington, D.C. LAVIV, which is made from a person’s own collagen-producing skin cells, is the first and only personalized cell therapy approved by the FDA for aesthetic use and was recently approved for the improvement of the appearance of moderate-to-severe “smile line” wrinkles (nasolabial folds). LAVIV is being investigated for the treatment of rolling, depressed acne scars, but is not currently approved for this indication.
